[13 March 2013]
Products Affected - Description
Diovan tablets, Novartis
40 mg, 100 count, unit-dose (NDC 00078-0423-06) - discontinued
80 mg, 100 count, unit-dose (NDC 00078-0358-06) - discontinued
80 mg, 14000 count, (NDC 00078-0358-33) - discontinued
160 mg, 100 count, unit-dose (NDC 00078-0359-06) - discontinued
160 mg, 7000 count, (NDC 00078-0359-17) - discontinued
320 mg, 3500 count (NDC 00078-0360-11) - discontinued
Reason for the Shortage
- Novartis is the sole supplier of valsartan tablets.
- Novartis could not provide a reason for the shortage.
- Novartis discontinued the unit dose and larger count presentations in late 2012.
Available Products
Diovan tablets, Novartis
40 mg, 30 count (NDC 00078-0423-15)
80 mg, 90 count (NDC 00078-0358-34)
160 mg, 90 count (NDC 00078-0359-34)
320 mg, 90 count, (NDC 00078-0360-34)
Estimated Resupply Dates
All Diovan presentations are available.
Related Shortages
Updated
March 13, 2013; February 1, 2013; December 17, 2012; October 9, 2012; July 25, 2012; July 5, 2012; June 6, 2012; May 29, 2012; May 9, 2012; April 13, 2012; March 23, 2012; March 8, 2012; February 17, 2012; February 3, 2012; January 27, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins